-
1
-
-
76749171200
-
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia
-
Conter V, Aricò M, Basso G, et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24:255-264, 2010
-
(2010)
Leukemia
, vol.24
, pp. 255-264
-
-
Conter, V.1
Aricò, M.2
Basso, G.3
-
2
-
-
76749102418
-
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000
-
Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
-
(2010)
Leukemia
, vol.24
, pp. 265-284
-
-
Möricke, A.1
Zimmermann, M.2
Reiter, A.3
-
3
-
-
76749095066
-
Long-term results of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report
-
Gaynon PS, Angiolillo AL, Carroll WL, et al: Long-term results of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report. Leukemia 24:285-297, 2010
-
(2010)
Leukemia
, vol.24
, pp. 285-297
-
-
Gaynon, P.S.1
Angiolillo, A.L.2
Carroll, W.L.3
-
4
-
-
76749112909
-
Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82,85,89,92 and 97
-
Escherich G, Horstmann MA, Zimmermann M, et al: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82,85,89,92 and 97. Leukemia 24: 298-308, 2010
-
(2010)
Leukemia
, vol.24
, pp. 298-308
-
-
Escherich, G.1
Horstmann, M.A.2
Zimmermann, M.3
-
5
-
-
76749136697
-
Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic
-
Stary J, Jabali Y, Trka J, et al: Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 24: 425-428, 2010
-
(2010)
Leukemia
, vol.24
, pp. 425-428
-
-
Stary, J.1
Jabali, Y.2
Trka, J.3
-
6
-
-
76749108502
-
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)
-
Silverman LB, Stevenson KE, O'Brien JE, et al: Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 24:320-334, 2010
-
(2010)
Leukemia
, vol.24
, pp. 320-334
-
-
Silverman, L.B.1
Stevenson, K.E.2
O'Brien, J.E.3
-
7
-
-
76749083364
-
Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98
-
Stark B, Nirel R, Avrahami G, et al: Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 24:419-424, 2010
-
(2010)
Leukemia
, vol.24
, pp. 419-424
-
-
Stark, B.1
Nirel, R.2
Avrahami, G.3
-
8
-
-
76749115697
-
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia
-
Schmiegelow K, Forestier E, Hellebostad M, et al: Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24:345-354, 2010
-
(2010)
Leukemia
, vol.24
, pp. 345-354
-
-
Schmiegelow, K.1
Forestier, E.2
Hellebostad, M.3
-
9
-
-
76749138468
-
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
-
Pui CH, Pei D, Sandlund JT, et al: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 24:371-382, 2010
-
(2010)
Leukemia
, vol.24
, pp. 371-382
-
-
Pui, C.H.1
Pei, D.2
Sandlund, J.T.3
-
10
-
-
67649410242
-
Treating childhood acute lymphoblastic leukemia without cranial irradiation
-
Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 2730-2741
-
-
Pui, C.H.1
Campana, D.2
Pei, D.3
-
11
-
-
76749093120
-
Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999
-
Tsuchida M, Ohara A, Manabe A, et al: Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 24:383-396, 2010
-
(2010)
Leukemia
, vol.24
, pp. 383-396
-
-
Tsuchida, M.1
Ohara, A.2
Manabe, A.3
-
12
-
-
76749170269
-
Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia
-
Liang DC, Yang CP, Lin DT, et al: Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 24:397-405, 2010
-
(2010)
Leukemia
, vol.24
, pp. 397-405
-
-
Liang, D.C.1
Yang, C.P.2
Lin, D.T.3
-
13
-
-
76749111534
-
Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001
-
Mitchell C, Richards S, Harrison CJ, et al: Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 24:406-418, 2010
-
(2010)
Leukemia
, vol.24
, pp. 406-418
-
-
Mitchell, C.1
Richards, S.2
Harrison, C.J.3
-
14
-
-
76749171660
-
Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004
-
Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al: Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 24:309-319, 2010
-
(2010)
Leukemia
, vol.24
, pp. 309-319
-
-
Kamps, W.A.1
Van Der Pal-de Bruin, K.M.2
Veerman, A.J.3
-
15
-
-
38949185746
-
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group
-
DOI 10.1182/blood-2007-04-084293
-
Lange BJ, Smith FO, Feusner J, et al: Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 111:1044-1053, 2008 (Pubitemid 351213382)
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1044-1053
-
-
Lange, B.J.1
Smith, F.O.2
Feusner, J.3
Barnard, D.R.4
Dinndorf, P.5
Feig, S.6
Heerema, N.A.7
Arndt, C.8
Arceci, R.J.9
Seibel, N.10
Weiman, M.11
Dusenbery, K.12
Shannon, K.13
Luna-Fineman, S.14
Gerbing, R.B.15
Alonzo, T.A.16
-
16
-
-
77449155696
-
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial
-
Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 586-595
-
-
Burnett, A.K.1
Hills, R.K.2
Milligan, D.W.3
-
17
-
-
34447282260
-
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of tokyo children's cancer study group
-
DOI 10.1002/pbc.20944
-
Tomizawa D, Tabuchi K, Kinoshita A, et al: Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatr Blood Cancer 49:127-132, 2007 (Pubitemid 47041100)
-
(2007)
Pediatric Blood and Cancer
, vol.49
, Issue.2
, pp. 127-132
-
-
Tomizawa, D.1
Tabuchi, K.2
Kinoshita, A.3
Hanada, R.4
Kigasawa, H.5
Tsukimoto, I.6
Tsuchida, M.7
-
18
-
-
28544438562
-
Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials [1]
-
DOI 10.1038/sj.leu.2403854, PII 2403854
-
Armendariz H, Barbieri MA, Freigeiro D, et al: Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials. Leukemia 19:2139-2142, 2005 (Pubitemid 41741606)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2139-2142
-
-
Armendariz, H.1
Fernandez, B.M.A.2
Freigeiro, D.3
Lastiri, F.4
Felice, M.S.5
Dibar, E.6
-
19
-
-
28544443076
-
Long-term results in children with AML: NOPHO-AML Study Group - Report of three consecutive trials
-
DOI 10.1038/sj.leu.2403962, PII 2403962
-
Lie SO, Abrahamsson J, Clausen N, et al: Long-term results in children with AML: NOPHO-AML Study Group - Report of three consecutive trials. Leukemia 19:2090-2100, 2005 (Pubitemid 41741601)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2090-2100
-
-
Lie, S.O.1
Abrahamsson, J.2
Clausen, N.3
Forestier, E.4
Hasle, H.5
Hovi, L.6
Jonmundsson, G.7
Mellander, L.8
Siimes, M.A.9
Yssing, M.10
Zeller, B.11
Gustafsson, G.12
-
20
-
-
23844541964
-
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials
-
DOI 10.1038/sj.leu.2403920, PII 2403920
-
Creutzig U, Zimmermann M, Ritter J, et al: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030-2042, 2005 (Pubitemid 41741595)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2030-2042
-
-
Creutzig, U.1
Zimmermann, M.2
Ritter, J.3
Reinhardt, D.4
Hermann, J.5
Henze, G.6
Jurgens, H.7
Kabisch, H.8
Reiter, A.9
Riehm, H.10
Gadner, H.11
Schellong, G.12
-
21
-
-
28544445097
-
Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
-
DOI 10.1038/sj.leu.2403925, PII 2403925
-
Smith FO, Alonzo TA, Gerbing RB, et al: Long-term results of children with acute myeloid leukemia: A report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 19:2054-2062, 2005 (Pubitemid 41741597)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2054-2062
-
-
Smith, F.O.1
Alonzo, T.A.2
Gerbing, R.B.3
Woods, W.G.4
Arceci, R.J.5
-
22
-
-
16644375118
-
Treatment and prevention of tumor lysis syndrome in children
-
Pession A, Barbieri E: Treatment and prevention of tumor lysis syndrome in children. Contrib Nephrol 147:80-92, 2005
-
(2005)
Contrib Nephrol
, vol.147
, pp. 80-92
-
-
Pession, A.1
Barbieri, E.2
-
23
-
-
28544452149
-
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report
-
DOI 10.1038/sj.leu.2403932, PII 2403932
-
Entz-Werle N, Suciu S, van der Werff ten Bosch J, et al: Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report. Leukemia 19: 2072-2081, 2005 (Pubitemid 41741599)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2072-2081
-
-
Entz-Werle, N.1
Suciu, S.2
Van, D.W.T.B.J.3
Vilmer, E.4
Bertrand, Y.5
Benoit, Y.6
Margueritte, G.7
Plouvier, E.8
Boutard, P.9
Vandecruys, E.10
Ferster, A.11
Lutz, P.12
Uyttebroeck, A.13
Hoyoux, C.14
Thyss, A.15
Rialland, X.16
Norton, L.17
Pages, M.-P.18
Philippe, N.19
Otten, J.20
Behar, C.21
Robert, A.22
Philippet, P.23
Maes, P.24
Plantaz, D.25
Falkenrodt, A.26
Fenneteau, O.27
Lagrange, M.28
Malet, A.M.29
Manel, A.M.30
Homolle, E.31
Dastugue, N.32
more..
-
24
-
-
28544450141
-
Treatment of childhood acute myeloblastic leukemia: Dose intensification improves outcome and maintenance therapy is of no benefit - Multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group
-
DOI 10.1038/sj.leu.2403867, PII 2403867
-
Perel Y, Auvrignon A, Leblanc T, et al: Treatment of childhood acute myeloblastic leukemia: Dose intensification improves outcome and maintenance therapy is of no benefit - Multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia 19: 2082-2089, 2005 (Pubitemid 41741600)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2082-2089
-
-
Perel, Y.1
Auvrignon, A.2
Leblanc, T.3
Michel, G.4
Reguerre, Y.5
Vannier, J.-P.6
Dalle, J.-H.7
Gandemer, V.8
Schmitt, C.9
Mechinaud, F.10
Lejars, O.11
Piguet, C.12
Couillaud, G.13
Pautard, B.14
Landman-Parker, J.15
Thuret, I.16
Aladjidi, N.17
Baruchel, A.18
Leverger, G.19
-
25
-
-
28544450726
-
Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000
-
Ravindranath Y, Chang M, Steuber CP, et al: Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-2116, 2005
-
(2005)
Leukemia
, vol.19
, pp. 2101-2116
-
-
Ravindranath, Y.1
Chang, M.2
Steuber, C.P.3
-
26
-
-
77953483479
-
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial
-
Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
-
(2010)
Lancet Oncol
, vol.11
, pp. 543-552
-
-
Rubnitz, J.E.1
Inaba, H.2
Dahl, G.3
-
27
-
-
28544447722
-
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
-
DOI 10.1038/sj.leu.2403924, PII 2403924
-
Gibson BE, Wheatley K, Hann IM, et al: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19:2130-2138, 2005 (Pubitemid 41741605)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2130-2138
-
-
Gibson, B.E.S.1
Wheatley, K.2
Hann, I.M.3
Stevens, R.F.4
Webb, D.5
Hills, R.K.6
De, G.S.S.N.7
Harrison, C.J.8
-
28
-
-
69849101233
-
Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group
-
Tsukimoto I, Tawa A, Horibe K, et al: Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 27:4007-4013, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 4007-4013
-
-
Tsukimoto, I.1
Tawa, A.2
Horibe, K.3
-
29
-
-
28544453186
-
Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results [2]
-
DOI 10.1038/sj.leu.2403959, PII 2403959
-
Quintana J, Advis P, Becker A, et al: Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results. Leukemia 19:2143-2146, 2005 (Pubitemid 41741607)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2143-2146
-
-
Quintana, J.1
Advis, P.2
Becker, A.3
Beresi, V.4
Campbell, M.5
Vines, E.F.6
Garcia, H.7
Salgado, C.8
Vargas, L.9
Rojas, J.10
Obando, M.11
Neira, L.12
Paez, E.13
Zolezzi, P.14
-
30
-
-
67650158965
-
COG AAML03P1: Efficacy and safety in a pilot study of intensive chemotherapy including gemtuzumab in children newly diagnosed with acute myeloid leukemia (AML)
-
(abstr 13)
-
Franklin J, Alonzo T, Hurwitz CA, et al: COG AAML03P1: Efficacy and safety in a pilot study of intensive chemotherapy including gemtuzumab in children newly diagnosed with acute myeloid leukemia (AML). ASH Annual Meeting Abstracts 112:56, 2008 (abstr 13)
-
(2008)
ASH Annual Meeting Abstracts
, vol.112
, pp. 56
-
-
Franklin, J.1
Alonzo, T.2
Hurwitz, C.A.3
-
31
-
-
40749150603
-
Acute lymphoblastic leukaemia
-
DOI 10.1016/S0140-6736(08)60457-2, PII S0140673608604572
-
Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008 (Pubitemid 351389536)
-
(2008)
The Lancet
, vol.371
, Issue.9617
, pp. 1030-1043
-
-
Pui, C.-H.1
Robison, L.L.2
Look, A.T.3
-
34
-
-
34147224008
-
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
-
DOI 10.1038/nature05690, PII NATURE05690
-
Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764, 2007 (Pubitemid 46582031)
-
(2007)
Nature
, vol.446
, Issue.7137
, pp. 758-764
-
-
Mullighan, C.G.1
Goorha, S.2
Radtke, I.3
Miller, C.B.4
Coustan-Smith, E.5
Dalton, J.D.6
Girtman, K.7
Mathew, S.8
Ma, J.9
Pounds, S.B.10
Su, X.11
Pui, C.-H.12
Relling, M.V.13
Evans, W.E.14
Shurtleff, S.A.15
Downing, J.R.16
-
35
-
-
76749108960
-
Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group
-
Salzer WL, Devidas M, Carroll WL, et al: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group. Leukemia 24:355-370, 2010
-
(2010)
Leukemia
, vol.24
, pp. 355-370
-
-
Salzer, W.L.1
Devidas, M.2
Carroll, W.L.3
-
36
-
-
46449085873
-
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials
-
Attarbaschi A, Mann G, Panzer-Grümayer R, et al: Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 26:3046-3050, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 3046-3050
-
-
Attarbaschi, A.1
Mann, G.2
Panzer-Grümayer, R.3
-
37
-
-
70449711127
-
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study
-
Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 27:5175-5181, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 5175-5181
-
-
Schultz, K.R.1
Bowman, W.P.2
Aledo, A.3
-
38
-
-
30444437486
-
Treatment of acute lymphoblastic leukemia
-
Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006
-
(2006)
N Engl J Med
, vol.354
, pp. 166-178
-
-
Pui, C.H.1
Evans, W.E.2
-
39
-
-
34548027243
-
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia
-
DOI 10.1182/blood-2006-07-038299
-
Nachman JB, Heerema NA, Sather H, et al: Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:1112-1115, 2007 (Pubitemid 47281405)
-
(2007)
Blood
, vol.110
, Issue.4
, pp. 1112-1115
-
-
Nachman, J.B.1
Heerema, N.A.2
Sather, H.3
Camitta, B.4
Forestier, E.5
Harrison, C.J.6
Dastugue, N.7
Schrappe, M.8
Pui, C.-H.9
Basso, G.10
Silverman, L.B.11
Janka-Schaub, G.E.12
-
40
-
-
70350680415
-
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia
-
Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243-1246, 2009
-
(2009)
Nat Genet
, vol.41
, pp. 1243-1246
-
-
Mullighan, C.G.1
Collins-Underwood, J.R.2
Phillips, L.A.3
-
41
-
-
77954500629
-
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol
-
Cario G, Zimmermann M, Romey R, et al: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393-5397, 2010
-
(2010)
Blood
, vol.115
, pp. 5393-5397
-
-
Cario, G.1
Zimmermann, M.2
Romey, R.3
-
42
-
-
77954516863
-
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/ Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
-
Harvey RC, Mullighan CG, Chen IM, et al: Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/ Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115:5312-5321, 2010
-
(2010)
Blood
, vol.115
, pp. 5312-5321
-
-
Harvey, R.C.1
Mullighan, C.G.2
Chen, I.M.3
-
43
-
-
57549087387
-
New genetic abnormalities and treatment response in acute lymphoblastic leukemia
-
Meijerink JP, den Boer ML, Pieters R: New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 46: 16-23, 2009
-
(2009)
Semin Hematol
, vol.46
, pp. 16-23
-
-
Meijerink, J.P.1
Den Boer, M.L.2
Pieters, R.3
-
44
-
-
58249140126
-
Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia
-
Graux C, Stevens-Kroef M, Lafage M, et al: Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 23:125-133, 2009
-
(2009)
Leukemia
, vol.23
, pp. 125-133
-
-
Graux, C.1
Stevens-Kroef, M.2
Lafage, M.3
-
45
-
-
58749095816
-
Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia
-
Coustan-Smith E, Mullighan CG, Onciu M, et al: Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009
-
(2009)
Lancet Oncol
, vol.10
, pp. 147-156
-
-
Coustan-Smith, E.1
Mullighan, C.G.2
Onciu, M.3
-
46
-
-
58749109707
-
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
-
Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 470-480
-
-
Mullighan, C.G.1
Su, X.2
Zhang, J.3
-
47
-
-
58749097408
-
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study
-
Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 10:125-134, 2009
-
(2009)
Lancet Oncol
, vol.10
, pp. 125-134
-
-
Den Boer, M.L.1
Van Slegtenhorst, M.2
De Menezes, R.X.3
-
48
-
-
67249146555
-
JAK mutations in high-risk childhood acute lymphoblastic leukemia
-
Mullighan CG, Zhang J, Harvey RC, et al: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414-9418, 2009
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 9414-9418
-
-
Mullighan, C.G.1
Zhang, J.2
Harvey, R.C.3
-
49
-
-
33747155025
-
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
-
DOI 10.1182/blood-2005-12-4956
-
Breit S, Stanulla M, Flohr T, et al: Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108: 1151-1157, 2006 (Pubitemid 44232009)
-
(2006)
Blood
, vol.108
, Issue.4
, pp. 1151-1157
-
-
Breit, S.1
Stanulla, M.2
Flohr, T.3
Schrappe, M.4
Ludwig, W.-D.5
Tolle, G.6
Happich, M.7
Muckenthaler, M.U.8
Kulozik, A.E.9
-
50
-
-
70149087158
-
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
-
Gutierrez A, Sanda T, Grebliunaite R, et al: High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114:647-650, 2009
-
(2009)
Blood
, vol.114
, pp. 647-650
-
-
Gutierrez, A.1
Sanda, T.2
Grebliunaite, R.3
-
51
-
-
43049139905
-
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
-
DOI 10.1038/nature06866, PII NATURE06866
-
Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114, 2008 (Pubitemid 351630327)
-
(2008)
Nature
, vol.453
, Issue.7191
, pp. 110-114
-
-
Mullighan, C.G.1
Miller, C.B.2
Radtke, I.3
Phillips, L.A.4
Dalton, J.5
Ma, J.6
White, D.7
Hughes, T.P.8
Le, B.M.M.9
Pui, C.-H.10
Relling, M.V.11
Shurtleff, S.A.12
Downing, J.R.13
-
52
-
-
77649214639
-
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group
-
Hertzberg L, Vendramini E, Ganmore I, et al: Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group. Blood 115:1006-1017, 2010
-
(2010)
Blood
, vol.115
, pp. 1006-1017
-
-
Hertzberg, L.1
Vendramini, E.2
Ganmore, I.3
-
53
-
-
38349068493
-
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences
-
van Grotel M, Meijerink JP, van Wering ER, et al: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 22:124-131, 2008
-
(2008)
Leukemia
, vol.22
, pp. 124-131
-
-
Van Grotel, M.1
Meijerink, J.P.2
Van Wering, E.R.3
-
54
-
-
61549114444
-
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
-
Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112:4178-4183, 2008
-
(2008)
Blood
, vol.112
, pp. 4178-4183
-
-
Yang, J.J.1
Bhojwani, D.2
Yang, W.3
-
55
-
-
57149118627
-
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia
-
DOI 10.1126/science.1164266
-
Mullighan CG, Phillips LA, Su X, et al: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380, 2008 (Pubitemid 352775249)
-
(2008)
Science
, vol.322
, Issue.5906
, pp. 1377-1380
-
-
Mullighan, C.G.1
Phillips, L.A.2
Su, X.3
Ma, J.4
Miller, C.B.5
Shurtleff, S.A.6
Downing, J.R.7
-
56
-
-
33745940511
-
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: A Children's Oncology Group study
-
DOI 10.1182/blood-2006-02-002824
-
Bhojwani D, Kang H, Moskowitz NP, et al: Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: A Children's Oncology Group study. Blood 108:711-717, 2006 (Pubitemid 44061374)
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 711-717
-
-
Bhojwani, D.1
Kang, H.2
Moskowitz, N.P.3
Min, D.-J.4
Lee, H.5
Potter, J.W.6
Davidson, G.7
Willman, C.L.8
Borowitz, M.J.9
Belitskaya-Levy, I.10
Hunger, S.P.11
Raetz, E.A.12
Carroll, W.L.13
-
57
-
-
69349101565
-
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia
-
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 41:1006-1010, 2009
-
(2009)
Nat Genet
, vol.41
, pp. 1006-1010
-
-
Papaemmanuil, E.1
Hosking, F.J.2
Vijayakrishnan, J.3
-
58
-
-
69349091330
-
Germline genomic variants associated with childhood acute lymphoblastic leukemia
-
Treviño LR, Yang W, French D, et al: Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009 41: 1001-1005, 2009
-
(2009)
Nat Genet 2009
, vol.41
, pp. 1001-1005
-
-
Treviño, L.R.1
Yang, W.2
French, D.3
-
59
-
-
77950955951
-
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence
-
Yang W, Trevino LR, Yang JJ, et al: ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia 24:894-896, 2010
-
(2010)
Leukemia
, vol.24
, pp. 894-896
-
-
Yang, W.1
Trevino, L.R.2
Yang, J.J.3
-
60
-
-
69849104865
-
The leukemic stem cell niche: Current concepts and therapeutic opportunities
-
Lane SW, Scadden DT, Gilliland DG: The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood 114:1150-1157, 2009
-
(2009)
Blood
, vol.114
, pp. 1150-1157
-
-
Lane, S.W.1
Scadden, D.T.2
Gilliland, D.G.3
-
63
-
-
34249674555
-
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors
-
DOI 10.1038/sj.leu.2404659, PII 2404659
-
Weisser M, Haferlach C, Hiddemann W, et al: The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia 21:1177-1182, 2007 (Pubitemid 46831805)
-
(2007)
Leukemia
, vol.21
, Issue.6
, pp. 1177-1182
-
-
Weisser, M.1
Haferlach, C.2
Hiddemann, W.3
Schnittger, S.4
-
64
-
-
0037062496
-
Chromosome translocations and covert leukemic clones are generated during normal fetal development
-
DOI 10.1073/pnas.112218799
-
Mori H, Colman SM, Xiao Z, et al: Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 99:8242-8247, 2002 (Pubitemid 34651037)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.12
, pp. 8242-8247
-
-
Mori, H.1
Colman, S.M.2
Xiao, Z.3
Ford, A.M.4
Healy, L.E.5
Donaldson, C.6
Hows, J.M.7
Navarrete, C.8
Greaves, M.9
-
65
-
-
70350497118
-
Novel prognostic subgroups in childhood 11q23/ MLL-rearranged acute myeloid leukemia: Results of an international retrospective study
-
Balgobind BV, Raimondi SC, Harbott J, et al: Novel prognostic subgroups in childhood 11q23/ MLL-rearranged acute myeloid leukemia: Results of an international retrospective study. Blood 114: 2489-2496, 2009
-
(2009)
Blood
, vol.114
, pp. 2489-2496
-
-
Balgobind, B.V.1
Raimondi, S.C.2
Harbott, J.3
-
66
-
-
44449151696
-
Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia
-
Gupta M, Raghavan M, Gale RE, et al: Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47:729-739, 2008
-
(2008)
Genes Chromosomes Cancer
, vol.47
, pp. 729-739
-
-
Gupta, M.1
Raghavan, M.2
Gale, R.E.3
-
67
-
-
50949113696
-
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
-
Raghavan M, Smith LL, Lillington DM, et al: Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 112:814-821, 2008
-
(2008)
Blood
, vol.112
, pp. 814-821
-
-
Raghavan, M.1
Smith, L.L.2
Lillington, D.M.3
-
68
-
-
69149083958
-
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia
-
Radtke I, Mullighan CG, Ishii M, et al: Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 106:12944-12949, 2009
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 12944-12949
-
-
Radtke, I.1
Mullighan, C.G.2
Ishii, M.3
-
69
-
-
69149100639
-
Acquired copy number alterations in adult acute myeloid leukemia genomes
-
Walter MJ, Payton JE, Ries RE, et al: Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 106:12950-12955, 2009
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 12950-12955
-
-
Walter, M.J.1
Payton, J.E.2
Ries, R.E.3
-
70
-
-
69249229646
-
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group
-
Ho PA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 113:6558-6566, 2009
-
(2009)
Blood
, vol.113
, pp. 6558-6566
-
-
Ho, P.A.1
Alonzo, T.A.2
Gerbing, R.B.3
-
71
-
-
41249103144
-
Modeling of C/EBPalpha Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating Cells
-
DOI 10.1016/j.ccr.2008.02.008, PII S1535610808000445
-
Kirstetter P, Schuster MB, Bereshchenko O, et al: Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13:299-310, 2008 (Pubitemid 351446194)
-
(2008)
Cancer Cell
, vol.13
, Issue.4
, pp. 299-310
-
-
Kirstetter, P.1
Schuster, M.B.2
Bereshchenko, O.3
Moore, S.4
Dvinge, H.5
Kurz, E.6
Theilgaard-Monch, K.7
Mansson, R.8
Pedersen, T.A.9
Pabst, T.10
Schrock, E.11
Porse, B.T.12
Jacobsen, S.E.W.13
Bertone, P.14
Tenen, D.G.15
Nerlov, C.16
-
72
-
-
10044294000
-
GATA1 mutations in Down syndrome: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia
-
Crispino JD: GATA1 mutations in Down syndrome: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 44:40-44, 2005
-
(2005)
Pediatr Blood Cancer
, vol.44
, pp. 40-44
-
-
Crispino, J.D.1
-
73
-
-
33845254595
-
Clinical implications of FLT3 mutations in pediatric AML
-
DOI 10.1182/blood-2006-03-009233
-
Meshinchi S, Alonzo TA, Stirewalt DL, et al: Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654-3661, 2006 (Pubitemid 44864541)
-
(2006)
Blood
, vol.108
, Issue.12
, pp. 3654-3661
-
-
Meshinchi, S.1
Alonzo, T.A.2
Stirewalt, D.L.3
Zwaan, M.4
Zimmerman, M.5
Reinhardt, D.6
Kaspers, G.J.L.7
Heerema, N.A.8
Gerbing, R.9
Lange, B.J.10
Radich, J.P.11
-
74
-
-
33344465478
-
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
-
DOI 10.1182/blood-2005-04-1466
-
Schnittger S, Kohl TM, Haferlach T, et al: KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107:1791-1799, 2006 (Pubitemid 43289355)
-
(2006)
Blood
, vol.107
, Issue.5
, pp. 1791-1799
-
-
Schnittger, S.1
Kohl, T.M.2
Haferlach, T.3
Kern, W.4
Hiddemann, W.5
Spiekermann, K.6
Schoch, C.7
-
75
-
-
33646432204
-
Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study
-
Cairoli R, Beghini A, Grillo G, et al: Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107:3463-3468, 2006
-
(2006)
Blood
, vol.107
, pp. 3463-3468
-
-
Cairoli, R.1
Beghini, A.2
Grillo, G.3
-
76
-
-
23744498520
-
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
-
DOI 10.1038/sj.leu.2403803
-
Nanri T, Matsuno N, Kawakita T, et al: Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22; q22). Leukemia 19:1361-1366, 2005 (Pubitemid 41136329)
-
(2005)
Leukemia
, vol.19
, Issue.8
, pp. 1361-1366
-
-
Nanri, T.1
Matsuno, N.2
Kawakita, T.3
Suzushima, H.4
Kawano, F.5
Mitsuya, H.6
Asou, N.7
-
77
-
-
33748467435
-
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study
-
DOI 10.1200/JCO.2006.06.9500
-
Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006 (Pubitemid 46630738)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.24
, pp. 3904-3911
-
-
Paschka, P.1
Marcucci, G.2
Ruppert, A.S.3
Mrozek, K.4
Chen, H.5
Kittles, R.A.6
Vukosavljevic, T.7
Perrotti, D.8
Vardiman, J.W.9
Carroll, A.J.10
Kolitz, J.E.11
Larson, R.A.12
Bloomfield, C.D.13
-
78
-
-
85015135541
-
Mutations in the Fms-related tyrosine kinase 3 (FLT3) gene independently predict poor outcome in acute myeloid leukemia (AML) with t(8;21): A study of the German-Austrian AML Study Group (AMLSG)
-
(abstr 825)
-
Paschka P, Du J, Schlenk RF, et al: Mutations in the Fms-related tyrosine kinase 3 (FLT3) gene independently predict poor outcome in acute myeloid leukemia (AML) with t(8;21): A study of the German-Austrian AML Study Group (AMLSG). Am Soc Hematol Annual Meeting Abstracts 114:340, 2009 (abstr 825)
-
(2009)
Am Soc Hematol Annual Meeting Abstracts
, vol.114
, pp. 340
-
-
Paschka, P.1
Du, J.2
Schlenk, R.F.3
-
79
-
-
39149092043
-
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples
-
Shih LY, Liang DC, Huang CF, et al: Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 22:303-307, 2008
-
(2008)
Leukemia
, vol.22
, pp. 303-307
-
-
Shih, L.Y.1
Liang, D.C.2
Huang, C.F.3
-
80
-
-
79952098374
-
Prevalence and clinical implications of N-RAS mutations in childhood AML: A report from the Children's Oncology Group
-
(abstr 3115)
-
Berman JN, Gerbing RB, Sung L, et al: Prevalence and clinical implications of N-RAS mutations in childhood AML: A report from the Children's Oncology Group. Am Soc Hematol Annual Meeting Abstracts 114:1211, 2009 (abstr 3115)
-
(2009)
Am Soc Hematol Annual Meeting Abstracts
, vol.114
, pp. 1211
-
-
Berman, J.N.1
Gerbing, R.B.2
Sung, L.3
-
81
-
-
61449204716
-
Clinical implications of molecular genetic aberrations in acute myeloid leukemia
-
Scholl S, Fricke HJ, Sayer HG, et al: Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 135:491-505, 2009
-
(2009)
J Cancer Res Clin Oncol
, vol.135
, pp. 491-505
-
-
Scholl, S.1
Fricke, H.J.2
Sayer, H.G.3
-
82
-
-
34547954572
-
The incidence and clinical significance of nucleophosmin mutations in childhood AML
-
DOI 10.1182/blood-2007-02-076604
-
Brown P, McIntyre E, Rau R, et al: The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 110:979-985, 2007 (Pubitemid 47267437)
-
(2007)
Blood
, vol.110
, Issue.3
, pp. 979-985
-
-
Brown, P.1
McIntyre, E.2
Rau, R.3
Meshinchi, S.4
Lacayo, N.5
Dahl, G.6
Alonzo, T.A.7
Chang, M.8
Arceci, R.J.9
Small, D.10
-
83
-
-
60149088611
-
Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
-
Hollink IH, Zwaan CM, Zimmermann M, et al: Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 23:262-270, 2009
-
(2009)
Leukemia
, vol.23
, pp. 262-270
-
-
Hollink, I.H.1
Zwaan, C.M.2
Zimmermann, M.3
-
84
-
-
70349579540
-
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
-
Schnittger S, Kern W, Tschulik C, et al: Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114:2220-2231, 2009
-
(2009)
Blood
, vol.114
, pp. 2220-2231
-
-
Schnittger, S.1
Kern, W.2
Tschulik, C.3
-
85
-
-
70350637903
-
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features
-
Haferlach C, Mecucci C, Schnittger S, et al: AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 114:3024-3032, 2009
-
(2009)
Blood
, vol.114
, pp. 3024-3032
-
-
Haferlach, C.1
Mecucci, C.2
Schnittger, S.3
-
86
-
-
55549101623
-
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
-
Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72, 2008
-
(2008)
Nature
, vol.456
, pp. 66-72
-
-
Ley, T.J.1
Mardis, E.R.2
Ding, L.3
-
87
-
-
70149093912
-
Recurring mutations found by sequencing an acute myeloid leukemia genome
-
Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
-
(2009)
N Engl J Med
, vol.361
, pp. 1058-1066
-
-
Mardis, E.R.1
Ding, L.2
Dooling, D.J.3
-
88
-
-
77952424259
-
Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study
-
Ho PA, Alonzo TA, Kopecky KJ, et al: Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study. Leukemia 24:909-913, 2010
-
(2010)
Leukemia
, vol.24
, pp. 909-913
-
-
Ho, P.A.1
Alonzo, T.A.2
Kopecky, K.J.3
-
89
-
-
77956050251
-
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
-
Thol F, Damm F, Wagner K, et al: Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614-616, 2010
-
(2010)
Blood
, vol.116
, pp. 614-616
-
-
Thol, F.1
Damm, F.2
Wagner, K.3
-
90
-
-
77950968519
-
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation
-
Chou WC, Hou HA, Chen CY, et al: Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115:2749-2754, 2010
-
(2010)
Blood
, vol.115
, pp. 2749-2754
-
-
Chou, W.C.1
Hou, H.A.2
Chen, C.Y.3
-
91
-
-
77952536841
-
IDH1 and IDH2 Gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
-
Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 Gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 2348-2355
-
-
Marcucci, G.1
Maharry, K.2
Wu, Y.Z.3
-
92
-
-
77952481300
-
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
-
Wagner K, Damm F, Gohring G, et al: Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356-2364, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 2356-2364
-
-
Wagner, K.1
Damm, F.2
Gohring, G.3
-
93
-
-
58849167390
-
A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects
-
Wouters BJ, Löwenberg B, Delwel R: A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects. Blood 113:291-298, 2009
-
(2009)
Blood
, vol.113
, pp. 291-298
-
-
Wouters, B.J.1
Löwenberg, B.2
Delwel, R.3
-
94
-
-
35348896184
-
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1
-
DOI 10.1182/blood-2007-02-073486
-
Wouters BJ, Jorda MA, Keeshan K, et al: Distinct gene expression profiles of acute myeloid/ T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 110:3706-3714, 2007 (Pubitemid 350159640)
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3706-3714
-
-
Wouters, B.J.1
Jorda, M.A.2
Keeshan, K.3
Louwers, I.4
Erpelinck-Verschueren, C.A.J.5
Tielemans, D.6
Langerak, A.W.7
He, Y.8
Yashiro-Ohtani, Y.9
Zhang, P.10
Hetherington, C.J.11
Verhaak, R.G.W.12
Valk, P.J.M.13
Lowenberg, B.14
Tenen, D.G.15
Pear, W.S.16
Delwel, R.17
-
95
-
-
63849197532
-
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features
-
Figueroa ME, Wouters BJ, Skrabanek L, et al: Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 113:2795-2804, 2009
-
(2009)
Blood
, vol.113
, pp. 2795-2804
-
-
Figueroa, M.E.1
Wouters, B.J.2
Skrabanek, L.3
-
97
-
-
73649110641
-
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia
-
Figueroa ME, Lugthart S, Li Y, et al: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13-27, 2010
-
(2010)
Cancer Cell
, vol.17
, pp. 13-27
-
-
Figueroa, M.E.1
Lugthart, S.2
Li, Y.3
-
98
-
-
33748413822
-
Acute myelogenous leukemia
-
Pizzo P, Poplack G (eds): Philadelphia, PA, Lippincott Williams & Wilkins
-
Golub T, Arceci RJ: Acute myelogenous leukemia, in Pizzo P, Poplack G (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2006, pp 591-644
-
(2006)
Principles and Practice of Pediatric Oncology
, pp. 591-644
-
-
Golub, T.1
Arceci, R.J.2
-
99
-
-
79952092290
-
Myeloid leukemias and myelodysplastic syndromesCarroll W, Finlay J (eds)
-
Boston, MA, Jones and Bartlett Publishers
-
Arceci RJ, Brown P: Myeloid leukemias and myelodysplastic syndromes, in Carroll W, Finlay J (eds): Cancer in Children: The Clinical Biology of Childhood Cancer. Boston, MA, Jones and Bartlett Publishers, 2010, pp 185-215
-
(2010)
Cancer in Children: The Clinical Biology of Childhood Cancer
, pp. 185-215
-
-
Arceci, R.J.1
Brown, P.2
-
100
-
-
57549090224
-
Treatment of childhood acute lymphoblastic leukemia
-
Stanulla M, Schrappe M: Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 46:52-63, 2009
-
(2009)
Semin Hematol
, vol.46
, pp. 52-63
-
-
Stanulla, M.1
Schrappe, M.2
-
101
-
-
33947588149
-
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
-
Pui CH, Jeha S: New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6:149-165, 2007
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 149-165
-
-
Pui, C.H.1
Jeha, S.2
-
102
-
-
33846882147
-
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
-
DOI 10.1182/blood-2006-06-027714
-
Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007 (Pubitemid 46220632)
-
(2007)
Blood
, vol.109
, Issue.3
, pp. 896-904
-
-
Moghrabi, A.1
Levy, D.E.2
Asselin, B.3
Barr, R.4
Clavell, L.5
Hurwitz, C.6
Samson, Y.7
Schorin, M.8
Dalton, V.K.9
Lipshultz, S.E.10
Neuberg, D.S.11
Gelber, R.D.12
Cohen, H.J.13
Sallan, S.E.14
Silverman, L.B.15
-
103
-
-
20644464975
-
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group
-
Berg SL, Blaney SM, Devidas M, et al: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol 23:3376-3382, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 3376-3382
-
-
Berg, S.L.1
Blaney, S.M.2
Devidas, M.3
-
104
-
-
65749095348
-
Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): Results of an international randomized trial in 3655 patients (Trial AEIOP-BFM ALL 2000)
-
(abstr 7)
-
Schrappe M, Zimmermann M, Möricke A, et al: Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): Results of an international randomized trial in 3655 patients (Trial AEIOP-BFM ALL 2000). Am Soc Hematol Annual Meeting Abstracts 112:9, 2008 (abstr 7)
-
(2008)
Am Soc Hematol Annual Meeting Abstracts
, vol.112
, pp. 9
-
-
Schrappe, M.1
Zimmermann, M.2
Möricke, A.3
-
105
-
-
34447519040
-
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial
-
DOI 10.1016/S0140-6736(07)61126-X, PII S014067360761126X
-
Pieters R, Schrappe M, De Lorenzo P, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 370:240-250, 2007 (Pubitemid 47082422)
-
(2007)
Lancet
, vol.370
, Issue.9583
, pp. 240-250
-
-
Pieters, R.1
Schrappe, M.2
De, L.P.3
Hann, I.4
De, R.G.5
Felice, M.6
Hovi, L.7
LeBlanc, T.8
Szczepanski, T.9
Ferster, A.10
Janka, G.11
Rubnitz, J.12
Silverman, L.13
Stary, J.14
Campbell, M.15
Li, C.-K.16
Mann, G.17
Suppiah, R.18
Biondi, A.19
Vora, A.20
Valsecchi, M.G.21
more..
-
106
-
-
0036606506
-
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
-
Pui CH, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002
-
(2002)
Lancet
, vol.359
, pp. 1909-1915
-
-
Pui, C.H.1
Gaynon, P.S.2
Boyett, J.M.3
-
107
-
-
33746149660
-
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner
-
DOI 10.1038/sj.leu.2404277, PII 2404277
-
Brown P, Levis M, McIntyre E, et al: Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20:1368-1376, 2006 (Pubitemid 44084049)
-
(2006)
Leukemia
, vol.20
, Issue.8
, pp. 1368-1376
-
-
Brown, P.1
Levis, M.2
McIntyre, E.3
Griesemer, M.4
Small, D.5
-
108
-
-
76249112147
-
Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options
-
Stumpel DJ, Schneider P, van Roon EH, et al: Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114:5490-5498, 2009
-
(2009)
Blood
, vol.114
, pp. 5490-5498
-
-
Stumpel, D.J.1
Schneider, P.2
Van Roon, E.H.3
-
109
-
-
77954721993
-
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: Biology and therapeutic targeting
-
Schafer E, Irizarry R, Negi S, et al: Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: Biology and therapeutic targeting. Blood 115:4798-4809, 2010
-
(2010)
Blood
, vol.115
, pp. 4798-4809
-
-
Schafer, E.1
Irizarry, R.2
Negi, S.3
-
110
-
-
61849122810
-
Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century
-
Pulte D, Gondos A, Brenner H: Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113:1408-1411, 2009
-
(2009)
Blood
, vol.113
, pp. 1408-1411
-
-
Pulte, D.1
Gondos, A.2
Brenner, H.3
-
111
-
-
47849108085
-
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
-
Stock W, La M, Sanford B, et al: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112:1646-1654, 2008
-
(2008)
Blood
, vol.112
, pp. 1646-1654
-
-
Stock, W.1
La, M.2
Sanford, B.3
-
112
-
-
70449700005
-
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: A report from the children's oncology group
-
Nachman JB, La MK, Hunger SP, et al: Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: A report from the children's oncology group. J Clin Oncol 27:5189-5194, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 5189-5194
-
-
Nachman, J.B.1
La, M.K.2
Hunger, S.P.3
-
113
-
-
0037362950
-
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials
-
DOI 10.1200/JCO.2003.02.053
-
Boissel N, Auclerc MF, Lheritier V, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003 (Pubitemid 46606434)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.5
, pp. 774-780
-
-
Boissel, N.1
Auclerc, M.-F.2
Lheritier, V.3
Perel, Y.4
Thomas, X.5
Leblanc, T.6
Rousselot, P.7
Cayuela, J.-M.8
Gabert, J.9
Fegueux, N.10
Piguet, C.11
Huguet-Rigal, F.12
Berthou, C.13
Boiron, J.-M.14
Pautas, C.15
Michel, G.16
Fiere, D.17
Leverger, G.18
Dombret, H.19
Baruchel, A.20
more..
-
114
-
-
11144266589
-
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands [1]
-
DOI 10.1038/sj.leu.2403538
-
de Bont JM, Holt B, Dekker AW, et al: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18:2032-2035, 2004 (Pubitemid 40028431)
-
(2004)
Leukemia
, vol.18
, Issue.12
, pp. 2032-2035
-
-
De, B.J.M.1
Van, D.H.B.2
Dekker, A.W.3
Van, D.D.-V.D.B.A.4
Sonneveld, R.5
Pieters, R.6
-
115
-
-
79952087452
-
Improved prognosis for older adolescents with acute lymphoblastic leukemia
-
(in press)
-
Pui CH, Pei D, Campana D, et al: Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (in press)
-
J Clin Oncol
-
-
Pui, C.H.1
Pei, D.2
Campana, D.3
-
116
-
-
41349100708
-
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
-
Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008
-
(2008)
Blood
, vol.111
, pp. 1827-1833
-
-
Goldstone, A.H.1
Richards, S.M.2
Lazarus, H.M.3
-
117
-
-
42949166852
-
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96
-
Ribera JM, Oriol A, Sanz MA, et al: Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 26:1843-1849, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 1843-1849
-
-
Ribera, J.M.1
Oriol, A.2
Sanz, M.A.3
-
118
-
-
47849095770
-
A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia
-
(abstr 587)
-
DeAngelo DJ, Dahlberg S, Silverman LB, et al: A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Am Soc Hematol Annual Meeting Abstracts 110:181a, 2007 (abstr 587)
-
(2007)
Am Soc Hematol Annual Meeting Abstracts
, vol.110
-
-
DeAngelo, D.J.1
Dahlberg, S.2
Silverman, L.B.3
-
119
-
-
67049098987
-
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen
-
Storring JM, Minden MD, Kao S, et al: Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 146:76-85, 2009
-
(2009)
Br J Haematol
, vol.146
, pp. 76-85
-
-
Storring, J.M.1
Minden, M.D.2
Kao, S.3
-
120
-
-
22044456688
-
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
-
DOI 10.1182/blood-2004-12-4797
-
Imai C, Iwamoto S, Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376-383, 2005 (Pubitemid 40967217)
-
(2005)
Blood
, vol.106
, Issue.1
, pp. 376-383
-
-
Imai, C.1
Iwamoto, S.2
Campana, D.3
-
121
-
-
31544467048
-
KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia [2]
-
DOI 10.1182/blood-2005-07-2809
-
Triplett B, Handgretinger R, Pui CH, et al: KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 107:1238-1239, 2006 (Pubitemid 43156333)
-
(2006)
Blood
, vol.107
, Issue.3
, pp. 1238-1239
-
-
Triplett, B.1
Handgretinger, R.2
Pui, C.-H.3
Leung, W.4
-
122
-
-
49649120397
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
-
Bargou R, Leo E, Zugmaier G, et al: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974-977, 2008
-
(2008)
Science
, vol.321
, pp. 974-977
-
-
Bargou, R.1
Leo, E.2
Zugmaier, G.3
-
123
-
-
70349390630
-
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)
-
Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957-966, 2009
-
(2009)
Lancet Oncol
, vol.10
, pp. 957-966
-
-
Veerman, A.J.1
Kamps, W.A.2
Van Den Berg, H.3
-
124
-
-
2342481169
-
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy
-
DOI 10.1200/JCO.2004.09.008
-
de Botton S, Coiteux V, Chevret S, et al: Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 22:1404-1412, 2004 (Pubitemid 41103622)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.8
, pp. 1404-1412
-
-
De, B.S.1
Coiteux, V.2
Chevret, S.3
Rayon, C.4
Vilmer, E.5
Sanz, M.6
De, L.S.J.7
Philippe, N.8
Baruchel, A.9
Leverger, G.10
Robert, A.11
San, M.J.12
Conde, E.13
Sotto, J.J.14
Bordessoule, D.15
Fegueux, N.16
Fey, M.17
Parry, A.18
Chomienne, C.19
Degos, L.20
Fenaux, P.21
more..
-
125
-
-
67651096058
-
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia
-
Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al: Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 113:5951-5960, 2009
-
(2009)
Blood
, vol.113
, pp. 5951-5960
-
-
Hollink, I.H.1
Van Den Heuvel-Eibrink, M.M.2
Zimmermann, M.3
-
126
-
-
77956275074
-
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group
-
Ho PA, Zeng R, Alonzo TA, et al: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 116: 702-710, 2010
-
(2010)
Blood
, vol.116
, pp. 702-710
-
-
Ho, P.A.1
Zeng, R.2
Alonzo, T.A.3
-
127
-
-
33845874653
-
Improved outcome after relapse in children with acute myeloid leukaemia
-
DOI 10.1111/j.1365-2141.2006.06419.x
-
Abrahamsson J, Clausen N, Gustafsson G, et al: Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 136:229-236, 2007 (Pubitemid 46020750)
-
(2007)
British Journal of Haematology
, vol.136
, Issue.2
, pp. 229-236
-
-
Abrahamsson, J.1
Clausen, N.2
Gustafsson, G.3
Hovi, L.4
Jonmundsson, G.5
Zeller, B.6
Forestier, E.7
Heldrup, J.8
Hasle, H.9
-
128
-
-
31444446828
-
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: A multicenter study by the PETHEMA Group
-
DOI 10.1200/JCO.2005.01.3359
-
Ortega JJ, Madero L, Martin G, et al: Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: A multicenter study by the PETHEMA Group. J Clin Oncol 23:7632-7640, 2005 (Pubitemid 46291827)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.30
, pp. 7632-7640
-
-
Ortega, J.J.1
Madero, L.2
Martin, G.3
Verdeguer, A.4
Garcia, P.5
Parody, R.6
Fuster, J.7
Molines, A.8
Novo, A.9
Deben, G.10
Rodriguez, A.11
Conde, E.12
De, L.S.J.13
Allegue, M.J.14
Capote, F.J.15
Gonzalez, J.D.16
Bolufer, P.17
Gonzalez, M.18
Sanz, M.A.19
-
129
-
-
71049144521
-
Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup trial INT0129
-
Gregory J, Kim H, Alonzo T, et al: Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 53:1005-1010, 2009
-
(2009)
Pediatr Blood Cancer
, vol.53
, pp. 1005-1010
-
-
Gregory, J.1
Kim, H.2
Alonzo, T.3
-
130
-
-
61949441174
-
Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009
-
(2009)
Blood
, vol.113
, pp. 1875-1891
-
-
Sanz, M.A.1
Grimwade, D.2
Tallman, M.S.3
-
131
-
-
16644373167
-
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European Acute Promyelocytic Leukemia Group
-
DOI 10.1200/JCO.2005.03.127
-
de Botton S, Fawaz A, Chevret S, et al: Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 23:120-126, 2005 (Pubitemid 41702630)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.1
, pp. 120-126
-
-
De, B.S.1
Fawaz, A.2
Chevret, S.3
Dombret, H.4
Thomas, X.5
Sanz, M.6
Guerci, A.7
San, M.J.8
De, L.S.J.9
Stoppa, A.M.10
Reman, O.11
Stamatoulas, A.12
Fey, M.13
Cahn, J.Y.14
Sotto, J.J.15
Bourhis, J.H.16
Parry, A.17
Chomienne, C.18
Degos, L.19
Fenaux, P.20
more..
-
132
-
-
70350621606
-
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen
-
Thirugnanam R, George B, Chendamarai E, et al: Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 15:1479-1484, 2009
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 1479-1484
-
-
Thirugnanam, R.1
George, B.2
Chendamarai, E.3
-
133
-
-
33846057947
-
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children: An Evidence-Based Review
-
DOI 10.1016/j.bbmt.2006.10.024, PII S1083879106007348
-
Oliansky DM, Rizzo JD, Aplan PD, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 13:1-25, 2007 (Pubitemid 46054985)
-
(2007)
Biology of Blood and Marrow Transplantation
, vol.13
, Issue.1
, pp. 1-25
-
-
Oliansky, D.M.1
Rizzo, J.D.2
Aplan, P.D.3
Arceci, R.J.4
Leone, L.5
Ravindranath, Y.6
Sanders, J.E.7
Smith III, F.O.8
Wilmot, F.9
McCarthy Jr., P.L.10
Hahn, T.11
-
134
-
-
0033959279
-
Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: Report from a t(1;22) study group
-
Bernstein J, Dastugue N, Haas OA, et al: Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: Report from a t(1;22) study group. Leukemia 14:216-218, 2000 (Pubitemid 30068396)
-
(2000)
Leukemia
, vol.14
, Issue.1
, pp. 216-218
-
-
Bernstein, J.1
Dastugue, N.2
Haas, O.A.3
Harbott, J.4
Heere, N.A.5
Huret, J.L.6
Landman-Parker, J.7
Lebeau, M.M.8
Leonard, C.9
Mann, G.10
Pages, M.P.11
Perot, C.12
Pirc-Danoewinata, H.13
Roitzheim, B.14
Rubin, C.M.15
Slociak, M.16
Viguie, F.17
-
135
-
-
0037232260
-
Acute megakaryoblastic leukaemia: A national clinical and biological study of 53 adult and childhood cases by the Groupe Francais d'Hematologie Cellulaire (GFHC)
-
DOI 10.1080/1042819021000040279
-
Duchayne E, Fenneteau O, Pages MP, et al: Acute megakaryoblastic leukaemia: A national clinical and biological study of 53 adult and childhood cases by the Groupe Francais d'Hematologie Cellulaire (GFHC). Leuk Lymphoma 44:49-58, 2003 (Pubitemid 36113829)
-
(2003)
Leukemia and Lymphoma
, vol.44
, Issue.1
, pp. 49-58
-
-
Duchayne, E.1
Fenneteau, O.2
Pages, M.-P.3
Sainty, D.4
Arnoulet, C.5
Dastugue, N.6
Garand, R.7
Flandrin, G.8
-
136
-
-
77949887020
-
FLT3- Mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
-
Pratz KW, Sato T, Murphy KM, et al: FLT3- mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115:1425-1432, 2010
-
(2010)
Blood
, vol.115
, pp. 1425-1432
-
-
Pratz, K.W.1
Sato, T.2
Murphy, K.M.3
-
137
-
-
33745626157
-
Role of allogeneic stem cell transplantation in FLT3/ ITD-positive AML
-
Meshinchi S, Arceci RJ, Sanders JE, et al: Role of allogeneic stem cell transplantation in FLT3/ ITD-positive AML. Blood 108:400-401, 2006
-
(2006)
Blood
, vol.108
, pp. 400-401
-
-
Meshinchi, S.1
Arceci, R.J.2
Sanders, J.E.3
-
138
-
-
77950612017
-
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
-
Pollard JA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115:2372-2379, 2010
-
(2010)
Blood
, vol.115
, pp. 2372-2379
-
-
Pollard, J.A.1
Alonzo, T.A.2
Gerbing, R.B.3
-
139
-
-
0038579430
-
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia
-
DOI 10.1182/blood-2002-10-3064
-
Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood 101:3398-3406, 2003 (Pubitemid 36857920)
-
(2003)
Blood
, vol.101
, Issue.9
, pp. 3398-3406
-
-
Sievers, E.L.1
Lange, B.J.2
Alonzo, T.A.3
Gerbing, R.B.4
Bernstein, I.D.5
Smith, F.O.6
Arceci, R.J.7
Woods, W.G.8
Loken, M.R.9
-
140
-
-
10044278287
-
Acute myeloid leukemia and Down syndrome evolution of modern therapy: State of the art review
-
Gamis AS: Acute myeloid leukemia and Down syndrome evolution of modern therapy: State of the art review. Pediatr Blood Cancer 44:13-20, 2005
-
(2005)
Pediatr Blood Cancer
, vol.44
, pp. 13-20
-
-
Gamis, A.S.1
-
141
-
-
38649095184
-
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: A report from the Children's Oncology Group Study POG 9421
-
DOI 10.1200/JCO.2007.13.2209
-
O'Brien MM, Taub JW, Chang MN, et al: Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: A report from the Children's Oncology Group Study POG 9421. J Clin Oncol 26:414-420, 2008 (Pubitemid 351171693)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.3
, pp. 414-420
-
-
O'Brien, M.M.1
Taub, J.W.2
Chang, M.N.3
Massey, G.V.4
Stine, K.C.5
Raimondi, S.C.6
Becton, D.7
Ravindranath, Y.8
Dahl, G.V.9
-
142
-
-
50049084037
-
The expanding role of arsenic in acute promyelocytic leukemia
-
Tallman MS: The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 45: S25-S29, 2008
-
(2008)
Semin Hematol
, vol.45
-
-
Tallman, M.S.1
-
143
-
-
35348849758
-
3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
-
(abstr 2)
-
3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL):
-
(2007)
J Clin Oncol
, vol.25
-
-
Powell, B.L.1
-
144
-
-
77649308061
-
Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes
-
(suppl)
-
Gore SD, Hermes-DeSantis ER: Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes. Cancer Control 16:2-10, 2009 (suppl)
-
(2009)
Cancer Control
, vol.16
, pp. 2-10
-
-
Gore, S.D.1
Hermes-DeSantis, E.R.2
-
145
-
-
34247369329
-
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European acute promyelocytic leukemia group
-
DOI 10.1200/JCO.2006.08.1596
-
Adès L, Chevret S, Raffoux E, et al: Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24:5703-5710, 2006 (Pubitemid 46631312)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.36
, pp. 5703-5710
-
-
Ades, L.1
Chevret, S.2
Raffoux, E.3
De, B.S.4
Guerci, A.5
Pigneux, A.6
Stoppa, A.M.7
Lamy, T.8
Rigal-Huguet, F.9
Vekhoff, A.10
Meyer-Monard, S.11
Maloisel, F.12
Deconinck, E.13
Ferrant, A.14
Thomas, X.15
Fegueux, N.16
Chomienne, C.17
Dombret, H.18
Degos, L.19
Fenaux, P.20
more..
-
146
-
-
0036625070
-
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
-
DOI 10.1182/blood-2001-12-0174
-
Estey EH, Giles FJ, Beran M, et al: Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222-4224, 2002 (Pubitemid 35332070)
-
(2002)
Blood
, vol.99
, Issue.11
, pp. 4222-4224
-
-
Estey, E.H.1
Giles, F.J.2
Beran, M.3
O'Brien, S.4
Pierce, S.A.5
Faderl, S.H.6
Cortes, J.E.7
Kantarjian, H.M.8
-
147
-
-
31744441028
-
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin
-
Lo Coco F, Ammatuna E, Noguera N: Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 4:57-62, 76-77, 2006
-
(2006)
Clin Adv Hematol Oncol
, vol.4
-
-
Lo Coco, F.1
Ammatuna, E.2
Noguera, N.3
-
148
-
-
33746655795
-
Features and outcome of neonatal leukemia in Japan: Experience of the Japan Infant Leukemia Study Group
-
DOI 10.1002/pbc.20599
-
Ishii E, Oda M, Kinugawa N, et al: Features and outcome of neonatal leukemia in Japan: Experience of the Japan infant leukemia study group. Pediatr Blood Cancer 47:268-272, 2006 (Pubitemid 44148042)
-
(2006)
Pediatric Blood and Cancer
, vol.47
, Issue.3
, pp. 268-272
-
-
Ishii, E.1
Oda, M.2
Kinugawa, N.3
Oda, T.4
Takimoto, T.5
Suzuki, N.6
Kosaka, Y.7
Ohara, A.8
Ogawa, A.9
Ishii, M.10
Sakata, N.11
Okamura, T.12
Koike, K.13
Kojima, S.14
Horibe, K.15
Mizutani, S.16
-
149
-
-
67650357912
-
Therapeutic targeting of MLL
-
Liedtke M, Cleary ML: Therapeutic targeting of MLL. Blood 113:6061-6068, 2009
-
(2009)
Blood
, vol.113
, pp. 6061-6068
-
-
Liedtke, M.1
Cleary, M.L.2
-
150
-
-
44249122620
-
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation
-
DOI 10.1111/j.1365-2141.2008.07100.x
-
Robinson BW, Behling KC, Gupta M, et al: Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol 141:827-839, 2008 (Pubitemid 351724853)
-
(2008)
British Journal of Haematology
, vol.141
, Issue.6
, pp. 827-839
-
-
Robinson, B.W.1
Behling, K.C.2
Gupta, M.3
Zhang, A.Y.4
Moore, J.S.5
Bantly, A.D.6
Willman, C.L.7
Carroll, A.J.8
Adamson, P.C.9
Barrett, J.S.10
Felix, C.A.11
-
151
-
-
59249100224
-
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
-
Yang JJ, Cheng C, Yang W, et al: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009
-
(2009)
JAMA
, vol.301
, pp. 393-403
-
-
Yang, J.J.1
Cheng, C.2
Yang, W.3
-
152
-
-
73349098768
-
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects
-
Treviño LR, Shimasaki N, Yang W, et al: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27:5972-5978, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 5972-5978
-
-
Treviño, L.R.1
Shimasaki, N.2
Yang, W.3
|